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Abstract 
Background: Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiographic syndrome formally rec-
ognized in 1996, which describes specific changes noted on neuroimaging thought to be related to impaired cerebral 
blood flow autoregulation and endothelial dysfunction. We report a case of PRES in the setting of increased ingestion 
of ondansetron; complicated by hemorrhagic transformation and refractory intracranial hypertension. We hypothesize 
an association of 5-HT3 antagonism and PRES.
Findings: This is a case study report; with review of previously published literature through PubMed search. We 
describe the case of a 25 year old man following bariatric surgery who increased his ingestion of ondansetron, 
taking up to 40 tablets/day due to excessive nausea and vomiting. The patient was hospitalized for progressively 
more severe headache of 1 week’s duration. Computed tomography (CT) revealed bilateral cerebral edema in the 
parietal and occipital lobes in the setting of elevated blood pressure (BP). Three days into his admission, following 
improvement in his BP with oral anti-hypertensive but continued use of the ondansetron, the patient developed near 
complete blindness. CT head imaging revealed progression of the posterior cerebral edema and intraparenchymal 
hemorrhage. He was admitted to our ICU and despite supportive treatment, his neurological examination worsened 
while CT head imaging findings remained stable. Invasive multimodality monitoring revealed elevated intracranial 
pressure. The patient was aggressively treated and after a prolonged hospitalization and rehabilitation course, made a 
significant recovery.
Conclusion: This case highlights a very rare potential neurological complication of ondansetron, a commonly used 
medication. We hypothesize an underlying association between PRES and 5-HT3 antagonism, via the latter’s potential 
role in endothelial dysfunction. Prompt recognition and treatment of PRES is essential, in order to prevent secondary 
cerebral injury and the associated potentially grave consequences.
Keywords: Stroke, Intracerebral hemorrhage, Cerebral autoregulation, Imaging, Intracranial hypertension, Intracranial 
pressure, Ondansetron, PRES (posterior reversible encephalopathy syndrome)
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Background
PRES is a clinical-radiographic syndrome of uncertain 
pathogenesis but of multiple heterogeneous etiologies 
that are commonly grouped together because of similar 
radiographic findings. Described using varying names in 
different case reports, the term reversible posterior leu-
koencephalopathy syndrome (RPLS) was first coined in 
1996 by Hinchey et  al. (1996). While the newly-coined 
term RPLS incorporated the same clinical and radio-
graphic findings of what was then known as the hyper-
tensive encephalopathy syndrome (Stott et  al. 2005; 
Schwartz et al. 1992; Schwartz et al. 1995; Hauser et al. 
1988). An extensive body of literature of this syndrome 
has since accumulated; and the prior term “RPLS” has 
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been recognized as misleading as well. The reasons being 
is that many cases can be irreversible or may even be 
fatal, and neuroimaging lesions may not be restricted to 
the white matter or posterior cortex as the name sug-
gests (Hinchey et al. 1996; Stott et al. 2005; Staykov and 
Schwab 2012; Covarrubias et al. 2002).
The pathogenesis of PRES remains unknown; however, 
several hypotheses have been suggested. PRES appears 
to be related to impaired cerebral blood flow autoregula-
tion, as well endothelial dysfunction (Hinchey et al. 1996; 
Stott et  al. 2005). Wide varieties of medical conditions 
and medications have also been implicated (Hinchey 
et  al. 1996; Stott et  al. 2005; Strandgaard and Paulson 
1984; Staykov and Schwab 2012). Autoregulatory failure, 
reactive focal vasoconstriction resulting in local hypop-
erfusion, cytotoxic cerebral edema, and cerebral infarc-
tion have been reported as well (Hinchey et  al. 1996; 
Stott et al. 2005; Strandgaard and Paulson 1984; Staykov 
and Schwab 2012; Hefzy et  al. 2009; Covarrubias et  al. 
2002; Golombeck et  al. 2013). Endothelial dysfunction 
has been implicated, particularly in PRES associated 
with pre-eclampsia, immunosuppressive and cytotoxic 
therapies (Hinchey et al. 1996; Stott et al. 2005; Staykov 
and Schwab 2012). The latter may lead to direct cerebral 
endothelial dysfunction and toxicity leading to blood–
brain barrier disruption and capillary leakage which may 
trigger further vasogenic edema (Stott et al. 2005; Strand-
gaard and Paulson 1984; Staykov and Schwab 2012). The 
clinical manifestations of PRES are varied and may range 
from insidious onset of headache, confusion, seizure, vis-
ual changes, or decreased level of consciousness to deep 
coma (Hinchey et  al. 1996; Stott et  al. 2005). Mortality 
directly related to PRES has been reported (Hinchey et al. 
1996; Alhilali et al. 2014; Golombeck et al. 2013). Treat-
ment of PRES remains supportive with control of blood 
pressure in hypertensive patients and removal of offend-
ing agents where identified.
In this report, we describe a case of PRES complicated 
by intracerebral hemorrhage in the setting of excessive 
ingestion of ondansetron following bariatric surgery. We 
hypothesize an association of 5-HT3 antagonism and 
PRES, implicating PRES as a rare potential complication 
of a commonly used medication.
Case report
A 25-year-old morbidly obese male underwent bariat-
ric surgery 3  months prior to presentation. In the week 
preceding his presentation to an outside hospital, he had 
increased his intake of ondansetron 4  mg tablets up to 
40 tablets/day because of intractable nausea and vomit-
ing. He was initially hospitalized for a progressively wors-
ening headache of 1  week duration. Initial computed 
tomography (CT) revealed bilateral cerebral edema in 
the parietal and occipital lobes in the setting of elevated 
blood pressure (BP). However, 3 days into his admission, 
following initial improvement in his blood pressure with 
oral anti-hypertensive medication, but in the setting of 
continued use of the ondansetron, he developed sudden 
onset near complete blindness with inability to count fin-
gers from one foot away but bare light perception. His 
blood pressure was measured as 190/110. Computed 
tomography (CT) head imaging revealed similar cerebral 
edema in the posterior cortex but new intra-parenchymal 
hemorrhage (Fig.  1). The patient was transferred to the 
intensive care unit (ICU) of our institution but despite 
supportive treatment, his condition worsened while CT 
imaging findings remained unchanged. No angiography 
was obtained, as it was felt to likely be inconclusive in the 
setting of massive hemorrhage. A CT venogram demon-
strated no evidence of venous sinus thrombosis. Invasive 
intracranial monitoring with a Licox® monitor revealed 
variable to elevated intracranial pressure (ICP) rang-
ing from 10 to 50 mm Hg. The patient was aggressively 
treated with hyperosmolar therapies and other support-
ive measures. He stabilized and after a protracted hospi-
talization was eventually discharged to rehabilitation. At 
the 12 week follow-up, he was noted to be independent 
in most of his activities of daily living. He was, however, 
left with significant visual impairment, leaving him only 
with the ability to count fingers in central vision, and only 
detect movement in his right visual fields. Follow-up CT 
of the head without contrast was obtained at that time, 
(Fig. 2) revealing resolution of the hematomas.
Discussion
This case highlights a rare potential neurological com-
plication of ondansetron; that of PRES complicated by 
intracerebral hemorrhage and refractory intracranial 
hypertension.
The details of PRES pathogenesis are not entirely clear, 
but the condition appears to be related to impaired cer-
ebral autoregulation and endothelial dysfunction. The 
association of PRES with diverse medications and clini-
cal entities could either suggest a unified pathogenesis or 
differing mechanisms yielding similar clinic-radiographic 
pictures. The predilection for primary involvement of 
the posterior brain regions is not well understood either. 
Several theories have been postulated; one thought to 
involve regional heterogeneity in the sympathetic inner-
vation of intracranial arterioles that serve to protect the 
brain during episodes of severe hypertension (Edvins-
son et al. 1976). In support of this, histochemical staining 
has demonstrated a greater concentration of adrenergic 
nerves around pial and intracerebral vessels in the ante-
rior circulation compared to the posterior circulation 
(Beausang-Linder and Bill 1981; Tecott et al. 1993).
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Ondansetron is a highly specific and selective seroto-
nin 5-HT3 receptor antagonist with low affinity for dopa-
mine receptors (Christofaki and Papaioannou 2014). 
5-HT3 receptors are widely expressed in the intracranial 
pial vasculature (Hefzy et al. 2009; Christofaki and Papa-
ioannou 2014; Tecott et  al. 1993; Kou et  al. 2002; Bétry 
et al. 2015). The mechanism through which ondansetron 
might contribute to the development of PRES may relate 
to its effect on blood vessels (Hefzy et al. 2009; Christo-
faki and Papaioannou 2014), as prolonged antagonism of 
these receptors (from the consistent and massive ondan-
setron ingestion by our patient) at the micro- and macro-
vascular level may ultimately have had a toxic effect on 
the vascular endothelium, leading to capillary leakage 
and blood–brain barrier disruption, and ultimately pro-
gressive vasogenic cerebral edema. It is also worth noting 
Fig. 1 a Non-contrast CT head (left to right: caudal to rostral) demonstrating multifocal (particularly in the posterior circulation) cerebral edema with 
associated intracerebral hemorrhage, mostly centered on left > right occipital lobes and extending into the fronto-temporal region. b Non-contrast 
CT follow-up at 12 weeks in same sequence. c CT venography (left: coronal, middle: sagittal, right: axial) demonstrating patency of visualized venous 
system; and without any evidence of venous obstructions
Fig. 2 a Cerebral autoregulatory curve under normal physiological condition. b Cerebral autoregulatory curve under impaired situation. (With 
permissions, courtesy of KO SB, J Stroke. 2013;15(2):99–108)
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that many cases of PRES associated with cytotoxic or 
immunosuppressive drugs (such as severolimus, cyclo-
sporine, tacrolimus, bevacizumab, cisplatin) have been 
reported in normotensive individuals, and in the setting 
of non-toxic levels or doses of these drugs, implying a 
direct cytotoxic-effect on the intracranial vasculature. 
Eight cases of ondansetron-related PRES have been 
reported to the FDA between January 2004 and October 
2012 ( 2015), though detailed information about these is 
unavailable.
We hypothesize that elevated blood pressure may 
have been an inciting event, which when coupled with 
ingestion of ondansetron culminated in the develop-
ment of PRES by means of pharmacologically ampli-
fied endothelial dysfunction and a resultant disruption 
of the brain–blood barrier (Hinchey et  al. 1996; Stott 
et  al. 2005; Glusker et  al. 2006; Covarrubias et  al. 2002; 
Ozkan et al. 2014; Schwartz et al. 1995). In this particu-
lar patient, the finding of progressive hemorrhagic PRES 
despite optimized control of our patient’s blood pressure, 
and the subsequent elevation in his ICP with otherwise 
unchanged imaging findings suggest that ondansetron led 
to uncontrolled vasogenic edema from endothelial dys-
function and possibly impaired cerebral autoregulation.
Hemorrhage in PRES has also been reported by others. 
For example, Hefzy et  al. reported incidence of hemor-
rhage with PRES in 15.2  % of the case series, with the 
highest rate of hemorrhage observed in the setting of 
immunosuppressive therapies (22 %) and the lowest rate 
in patients with eclampsia (5.5 %) (Hefzy et al. 2009). This 
higher incidence of hemorrhagic PRES in the setting of 
concurrent immunosuppressive or cytotoxic drugs may 
relate to a direct cytotoxic effect on the cerebral micro-
circulation and blood brain barrier.
PRES may lead to permanent injury or death. His-
torically, PRES associated with hemorrhage has been 
reported to be associated with 16–29  % mortality rate 
(Akins et  al. 2014) whereas most recent reports indi-
cate 3–6  % mortality during a range of follow-up time 
(generally 1–3  months) (Akins et  al. 2014; Fugate and 
Rabinstein 2015; Moon et  al. 2013). Severe neurologi-
cal injury and fatality in PRES have most often occurred 
in relation to intracranial hemorrhage, posterior fossa 
edema with brainstem compression or herniation, or 
diffuse cerebral edema and increased intracranial pres-
sure (Fugate and Rabinstein 2015). Some long-term 
recognized sequelae of PRES include persistent hemipa-
resis, seizures, impaired vision, and decreased cognition 
(Fugate and Rabinstein 2015). Additionally, several stud-
ies have reported that incomplete recovery in PRES is 
often associated with intracerebral hemorrhage (Fugate 
and Rabinstein 2015; Moon et  al. 2013; Shaharir et  al. 
2013).
We recognize several limitations to this case report. 
The inability in further obtaining any further information 
regarding the eight prior cases of ondansetron-related 
PRES (safety reports of the FDA) adds to the limitations 
of this case report. The absence of cerebral angiography 
restricts any potential insight towards an underlying vas-
cular abnormality that may have contributed to this pres-
entation albeit highly unlikely given lack of clear clinical 
stigmata during subsequent follow-up routine CT head. 
Additionally, it is difficult to completely exclude that 
uncontrolled hypertension was the cause in this case, 
although the severity of the symptoms, their refractori-
ness to anti-hypertensive therapy and the association 
with prolonged high-dose ingestion of ondansetron 
appears to implicate this drug as at least a potentially 
contributing agent.
Conclusion
PRES is a clinico-radiographic syndrome of heterogene-
ous etiologies that are poorly understood, but grouped 
together because of similar neuro-imaging findings. Dif-
ferent etiologies have been implicated, with uncontrolled 
blood pressure elevation as the most frequent culprit. 
Furthermore, systemic medications and other cytotoxic 
or immunosuppressive medication can contribute or 
solely lead to this condition by separate mechanisms. 
Prompt recognition and treatment of the precipitating 
condition and prevention of secondary insults such as 
intracranial hemorrhage, intracranial hypertension, and 
cerebral infarction are essential.
We believe physicians need to have greater aware-
ness of this potential complication of a routinely used 
medication. In this manuscript, we report an observa-
tion of ondansetron overdosage associated with hyper-
tension leading to PRES with potentially disastrous 
consequences. We propose a possible causative mecha-
nism, mainly focused on ondansetron’s anti-seroton-
ergic properties and their relationship with cerebral 
autoregulation.
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